Takeda Chemical Industries, Inc.

Takeda Pharmaceutical Company Limited

Other

Shiseido Company, Limited

Tomohiro Kawamoto

Hiroyuki Kimura

Naoyuki Kanzaki

Yasushi Shintani

Kazuo Nakahama

Kazunori Nishi

Fumio Itoh

Ohji Ifuku

Junji Matsui

Hiromi Kobayashi

Shigenori Ohkawa

Eiji Kimura

Shuji Kitamura

Jun Kunitomo

Seiji Miwatashi

Morihisa Saitoh

Hidekazu Sawada

Katsuhito Murase

Kenichi Naruo

Hiroki Iwashita

Hideki Igata

Mitsuru Sasaki

For the purpose of providing a GSK-3&#x3b2; inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3&#x3b2;-related pathology or disease, the present invention provides a GSK-3&#x3b2; inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

GSK-3&#x3b2; inhibitor

A JNK inhibitor containing a compound having an isoquinolinone skeleton or a salt thereof, such as a compound represented by the formula wherein ring A and ring B are each an optionally substituted benzene ring, X is &#x2014;O&#x2014;, &#x2014;N&#x2550;, &#x2014;NR&#x2014; or &#x2014;CHR&#x2014;, Ris an acyl group, an optionally esterified or thioesterified carboxyl group, an optionally substituted carbamoyl group or an optionally substituted amino group and the like, a broken line shows a single bond or a double bond, and Ris a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like, and the like.

JNK inhibitor

The present invention relates to a c-Jun N-terminal kinase inhibitor containing an azole compound (I) substituted by a nitrogen-containing aromatic group having substituent(s)(except a compound represented by the formula: ) or a salt thereof or a prodrug thereof.

Sodium bicarbonate cotransporter protein

A microorganism resistant to a threonine analogue, which has a plasmid containing part or whole of a biotin operon; and a process for producing biotin, which comprises culturing a microorganism described above in a medium to produce and accumulate biotin in the medium, and collecting biotin.

Microorganism resistant to threonine analogue and production of biotin

This invention relates to a novel calpain having a proteolytic activity, its partial peptide or a salt either of them, a DNA coding for the protein, a recombinant vector comprising the DNA, a transformant carrying the recombinant vector, a process for producing the protein, a pharmaceutical composition comprising the DNA, an antibody against the protein, a method for screening for a compound which activates or inhibits a proteolytic activity of the protein, a kit for screening for the compound, and a compound which activates or inhibits a proteolytic activity of the protein which is identified by the screening method or the kit. The DNA coding for the protein of the present invention can be used as a therapeutic and prophylactic composition for a variety of diseases including tumor, cerebral apoplexy, cerebral infarction, subarachnoid hemorrhage, Alzheimer's disease, myodystrophy, cataract, ischemic heart disease, atherosclerosis, arthritis, and collagen disease. Furthermore, the protein of the present invention is useful as a screening reagent for any compounds which activates or inhibits the function of the protein of the present invention. In addition, the antibody against the protein of the present invention specifically recognizes the protein of the present invention and can be used in the quantitative determination of the protein of the present invention in a test fluid.

Proteins, their production and use

Growing community of inventors

Takatsuki, Japan

Tomohiro Kawamoto